Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Novo Nordisk A/S (NVO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Novo Nordisk ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
106.57 -0.71    -0.66%
12:11:53 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US6701002056 
CUSIP:  670100205
  • Volume: 386,826
  • Bid/Ask: 106.53 / 106.62
  • Day's Range: 106.27 - 107.19
Novo Nordisk ADR 106.57 -0.71 -0.66%
Period Ending: 2021
30/09
2021
30/06
2021
31/03
2020
31/12
Period Length: 9 Months 6 Months 3 Months 12 Months
Net Income/Starting Line 36865 24746 12623 42138
Cash From Operating Activities 58017 36510 11255 51951
Depreciation/Depletion 3943 2594 1377 5753
Amortization - - - -
Deferred Taxes - - - -
Non-Cash Items 23749 15281 4349 18841
Cash Receipts - - - -
Cash Payments - - - -
Cash Taxes Paid 8580 7808 5931 10106
Cash Interest Paid 141 85 50 422
Changes in Working Capital -6540 -6111 -7094 -14781
Cash From Investing Activities -11002 -6367 -3481 -22436
Capital Expenditures -5071 -3383 -1499 -22081
Other Investing Cash Flow Items, Total -5931 -2984 -1982 -355
Cash From Financing Activities -30042 -18311 -14475 -32244
Financing Cash Flow Items - - 2329 -
Total Cash Dividends Paid -21517 -13496 -13495 -20121
Issuance (Retirement) of Stock, Net -11935 -8400 -2960 -16855
Issuance (Retirement) of Debt, Net 3410 3585 -349 4732
Foreign Exchange Effects 291 169 154 -456
Net Change in Cash 17264 12001 -6547 -3185
Beginning Cash Balance - - - -
Ending Cash Balance - - - -
Free Cash Flow - - - -
Free Cash Flow Growth - - - -
Free Cash Flow Yield - - - -
* In Millions of DKK (except for per share items)
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVO Comments

Write your thoughts about Novo Nordisk A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jokers R Us
Jokers R Us 10 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This company is a powerhouse
daemin jeong
daemin jeong Nov 02, 2021 5:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sure, best company
Jokers R Us
Jokers R Us Sep 08, 2021 3:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Name a better company
Jokers R Us
Jokers R Us Jul 27, 2021 6:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Great company
David Dahan
David Dahan May 24, 2021 10:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NVO WILL BUY ORMP AT 30 $
Petri Kiljunen
Petri Kiljunen Feb 16, 2021 10:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
and Gals..! :D
Petri Kiljunen
Petri Kiljunen Feb 16, 2021 10:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Guys, think about this and USA market...and market all around the world. The same Type 2 diabetes drug semaglutide seems to work well against obesity.  This can be a massive hit! https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data
Ralf Adams
Ralf Adams Feb 16, 2021 10:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Seems that the importance of these results is being overlooked at the moment for some strange reason.  Might be a good idea to stay in long.
christopher brown
christopher brown Aug 01, 2019 1:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very good long term investment
Jorgen Andersen
Jorgen Andersen Feb 06, 2019 4:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone got a view on how much the plans to reduce medical prices will affect the share price ?
Jens Kramer
Jens Kramer Feb 06, 2019 4:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
My bet is that the stock price will have an increase in growth on the long term. Not sure about short term as they might need to spend to expand production, however, they might get subsidies for this.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email